Fig. 7.

Endothelial-specific deletion of PDGFR-b sensitizes glioma-associated ECs and tumors to anti-VEGF treatment. a–c Tie2-Cre;Pdgfrb^fl/fl mice were generated by crossing Tie2-Cre mice with Pdgfrb^fl/fl mice. a Schematic approach. b ECs were isolated from mouse aortas. Heart tissue and ECs were subjected to immunoblot analysis. c Mouse embryos were imaged (n = 5). d–h The primary GBM in Ntv-a;Ink4a-Arf^−/−;Pten^−/−;LSL-Luc donor mice was induced by RCAS-mediated somatic gene transfer. Single-cell tumor suspension was implanted into Pdgfrb^fl/fl (WT) or Tie2-Cre;Pdgfrb^fl/fl (PDGFR-β-ΔEC) recipient mice, followed by treatment with B20 antibody and IgG. d Schematic approach. e Animal survival was monitored for 60 days after injection (n = 7 mice). MS median survival. P values were determined by log-rank tests. f Tumor growth was analyzed by whole-body bioluminescence imaging. Left, representative images. Right, quantitative analysis of integrated luminescence in tumors at day 25–28 (n = 3–6 mice, mean ± SEM). g Tumor sections were stained with H&E dyes. Representative data are shown (n = 3–4 mice). Scale bar: 100 μm. h Tumor sections were immunostained with anti-CD31 antibody. Left, representative images. Right, quantitative analysis of CD31 fluorescence area (n = 4–5 mice, mean ± SEM). Scale bar: 100 μm. i Tumor sections were immunostained with anti-CD31 and anti-FSP-1 antibodies. Representative images are shown (n = 4–5 mice). Scale bar: 100 μm